You are here:

Supporting pregnancy

Published on


Valproate and pregnancy awareness survey 2019

Are you a woman or girl under the age of 55 who is taking, or has taken, sodium valproate since 1 August 2018? We want to find out how much women and girls of childbearing age know about the risks associated with the epilepsy medication, if taken during pregnancy.

For every baby exposed to sodium valproate during pregnancy, there is up to a 40 per cent risk of the baby being born with a physical or neurodevelopmental disability.

Valproate and pregnancy awareness survey 2019

We would be grateful if you could fill in our survey at the link below to help us assess:

  • how effective new regulations around prescribing the drug are;
  • whether women and girls are aware of the risks;
  • and how they feel about the pregnancy prevention programme.

Take the valproate and pregnancy survey 

New regulations

New regulations around prescribing sodium valproate (also known as Epilim, Episenta, Epival, Convulex, Depakote, Kentilim, Orlept, Syonell, Valpal and Valproic acid) were introduced by the Medicines and Healthcare products Agency in April 2018.

The survey has been launched by the three charities Epilepsy Society, Epilepsy Action and Young Epilepsy. The survey will run for four weeks until Tuesday 19 November 2019.

You should never stop taking sodium valproate without consulting your doctor.

Sodium valproate

Sodium valproate is an epilepsy drug prescribed for all seizure types including absence, myoclonus and tonic clonic seizures. New regulations have been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) around the way in which the drug, sodium valproate is prescribed to women and girls of childbearing age. 


Our campaigns team lobby government and decision-makers on the issues that matter to people with epilepsy. From safer medicines for pregnant women to the dangers of online trolling, and from medicines supply to public transport access, we raise awareness of the daily challenges facing people with epilepsy.


We send monthly e-newsletters to keep you informed with tips for managing epilepsy, the latest news, inspirational stories, fundraising opportunities and further information from Epilepsy Society.

Read our privacy policy

It is always your choice as to whether you want to receive information from us. You may opt-out of our marketing communications by clicking the ‘unsubscribe’ link at the end of our marketing emails or through our unsubscribe number 01494 601 300.